Lenvatinib, Nivolumab, and Chemo in Stomach Cancer with Ascites
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (lenvatinib and nivolumab) plus chemotherapy for people with advanced stomach cancer that has caused fluid buildup in the belly. The goal is to see if this combination can help shrink the cancer and reduce the fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer that has spread to the lining of your belly, causing a moderate to large amount of fluid buildup (ascites).
- Your tumor has a high level of a protein called PD-L1 (score 5 or higher).
- You have not had chemotherapy or immunotherapy for cancer that has spread, or if you had chemo after surgery, it has been more than 6 months since you finished.
- You are generally healthy enough to manage daily activities (ECOG score 0 or 1) and have good organ function (kidneys, liver, blood counts).
- You are not pregnant, not breastfeeding, and willing to use effective birth control during the study and for 5 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a new combination of chemotherapy (XELOX) plus two immunotherapy/targeted drugs (Sintilimab and Lenvatinib) in people with advanced stomach cancer that produces a high level of a protein called AFP. It aims to see if this combination is safe and can shrink tumors when given as the first treatment.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.